-
Professor Zhang Xi: How to combine CAR-T cell therapy with clinical needs
Time of Update: 2021-04-18
Professor Zhang Xi took the team's development history of CAR-T cell research and development in recent years as an example, and vividly demonstrated their efforts in combining CAR-T with clinical needs.
-
BeiGene announces the clinical data of Sitravatinib combined with Bazeran® at the American Association for Cancer Research (AACR) 2021 Annual Meeting
Time of Update: 2021-04-18
Data from an ongoing phase 1b clinical trial of sitravatinib combined with Baizian® shows that the combination of drugs targets patients with unresectable or metastatic melanoma that is refractory or
-
2021 AACR | Selpercatinib in the treatment of RET fusion-positive solid tumors with an ORR of 47%
Time of Update: 2021-04-18
In an international multi-center registration trial, the efficacy and safety of selpercatinib in the treatment of RET fusion-positive non-lung cancer/non-thyroid cancer patients were evaluated.
Research method: The LIBRETTO-001 study is a phase 1/2 clinical trial (NCT03157128), which included adult patients with locally advanced or metastatic RET fusion-positive non-lung cancer/non-thyroid cancer (data deadline: March 19, 2021) .
-
There are differences between men and women: the fatter the men and the thicker the waist of women, the higher the risk of colorectal cancer!
Time of Update: 2021-04-18
Recently, researchers from the University of Bristol in the United Kingdom used a naturally occurring test called Mendelian randomization to use genetic information to better understand the causality of adjustable factors and studied two different measures of obesity-namely Whether body mass index (BMI) and waist-to-hip ratio (WHR) are associated with the risk of CRC in men and women, respectively.
-
Wei Xiawei's team from Sichuan University discovers a potential target for the treatment of lung cancer
Time of Update: 2021-04-18
The study found that the expression of CXCR2 in human lung cancer stroma and tumor cells is elevated, which is related to the prognosis of patients.
The study found that the expression of CXCR2 in human lung cancer stroma and tumor cells is elevated, which is related to the prognosis of patients.
-
2021 AACR │One more city, the king reaches the top!
Time of Update: 2021-04-18
Based on its excellent efficacy and safety data and pharmacoeconomic advantages, tislelizumab may become the main drug in the second/third-line treatment of locally advanced or metastatic NSCLC in China and even the world in the future.
-
How to choose EGFR-TKI targeted therapy?
Time of Update: 2021-04-18
kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis article, systematically summarized the toxicity of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) targeted therapy for lung cancer, from each Based on the systemic adverse events and specific adverse events of EGFR-TKI, a toxicity profile used to guide clinical practice was drawn.
-
Shanghai Expert Consensus on the Clinical Application of Oncolytic Viruses in the Treatment of Malignant Tumors (Version 2021)-Summary
Time of Update: 2021-04-18
In clinical work, most physicians lack sufficient understanding of the mechanism of action of oncolytic virus drugs and evidence-based medicine, and the clinical application lacks a unified standard.
-
Chen Xiang/Han Leng/Liu Hong/Jing Ying collaborate to reveal gender-related differences in immune-related adverse reactions of cancer immunotherapy
Time of Update: 2021-04-18
In recent years, as more and more cancer patients adopt immunotherapy, immune related adverse events (irAE) have also attracted the attention of researchers. There is evidence that there are gender
-
Molecular Cancer | Naval Medical University Yang Bo and others develop new methods to better diagnose prostate cancer
Time of Update: 2021-04-18
The research passed Comparing the RNA sequencing data of circulating exosomes with the corresponding data in tissues illustrates the different characteristics of emRNA compared with tissue mRNA.
-
Can Bristol-Myers Squibb continue to write the myth, Opdivo Phase III clinical trial reaches the primary endpoint
Time of Update: 2021-04-18
Opdivo first-line combination therapy Bristol-Myers Squibb Opdivo first-line combination therapy Phase 3 CheckMate -648 trial is mainly to evaluate Opdivo (nivolumab) combined with chemotherapy or Opdivo combined with Yervoy (ipilimumab) for unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) The patient's treatment effect.
-
Voice of China | sitravatinib + tislelizumab in the treatment of advanced melanoma, DCR reaches 88%!
Time of Update: 2021-04-18
Methods Researchers report the results of the melanoma cohort in an ongoing multi-cohort phase Ⅰb study (BGB-900-103; NCT03666143), which aims to evaluate sitravatinib combined with tislelizumab in advanced solid tumors Safety/tolerability and preliminary anti-tumor activity.
-
2021 AACR | IMbrave150 study is updated again: immune combination can benefit high-risk liver cancer patients!
Time of Update: 2021-04-18
The global phase 2 FOENIX-CCA2 study (NCT02052778) aims to evaluate the efficacy and safety of futibatinib in patients with FGFR2 gene fusion/rearrangement iCCA.
Methods: The study included patients with unresectable/metastatic iCCA who had FGFR2 fusion/rearrangement, and had disease progression after receiving ≥1 line therapy.
-
The O-drug combination regimen in the treatment of Chinese patients with advanced gastric cancer has an amazing survival benefit curve of OS and PFS!
Time of Update: 2021-04-18
Preface As the world's first PD-1 inhibitor approved for marketing, the clinical research carried out by nivolumab (Odivo, drug O) has always been a vane for the development of immuno-oncology treatm
-
The risk of postoperative recurrence of lung cancer is expected to be greatly reduced. The use of O-drug combined with chemotherapy for neoadjuvant significantly improves the rate of complete tumor pathology
Time of Update: 2021-04-18
The 2021 American Association for Cancer Research (AACR) annual meeting will be held on April 10 At the opening, CheckMate-816 clinical research data on non-small cell lung cancer was released at the conference: Compared with chemotherapy alone, operable patients in stage IB~IIIA receive 3 cycles of O-drug combined with chemotherapy before surgery , Can significantly improve tumor pathological complete remission (pCR).
-
What is the quality of life of bladder cancer patients?
Time of Update: 2021-04-18
In short, compared with the HRQOL reported by the general population and other common cancer patients, the HRQOL of bladder cancer patients is worse, and it seems that it has nothing to do with the treatment and the stage of the disease.
-
Express | Arvinas announces the molecular structure of the star PROTAC
Time of Update: 2021-04-18
▎The content team editor of WuXi AppTec recently, Arvinas, a company dedicated to the development of targeted protein degradation therapies, announced at the American Association for Cancer Research (AACR) annual meeting the molecular structure and Medicinal chemistry optimization process.
-
Nature | Bacterial antigen peptides identified in melanoma provide a new mechanism for bacteria to affect immune system activation and anti-tumor treatment response
Time of Update: 2021-04-18
The researchers first performed 16S rRNA sequencing on 17 melanoma metastatic tumor samples from 9 patients and identified 41 types of bacteria, and the bacterial composition between different metastases of the same patient and tumors of different patients were highly similar.
-
[Nature Sub-Journal] A breakthrough discovery: it has been ignored for decades, it can increase the survival rate of patients with bowel cancer
Time of Update: 2021-04-18
In order to answer these questions, researchers from the Bison Institute (BI) of the Cancer Research UK and Memorial Sloan Kettering Cancer Center collated and analyzed data from the largest published tumor sample data set, which includes the mitochondrial genome The data and the corresponding clinical results of the patient.
-
Professor Yang Jin: A new strategy for breast cancer endocrine combined targeted therapy | 2021 CSCO BC
Time of Update: 2021-04-18
A number of large-scale clinical studies at home and abroad have shown that the combination of CDK4/6 inhibitors and endocrine first-line/second-line treatment improves the progression-free survival (PFS) and OS of breast cancer patients, indicating the significant efficacy advantage of this treatment program.
